- Home
- EVCM vs OMER Comparison
EVCM vs OMER Comparison
Compare EVCM & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVCM | OMER |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | EVCM | OMER |
|---|---|---|
| Price | $9.19 | $16.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $11.00 | ★ $27.50 |
| AVG Volume (30 Days) | 103.6K | ★ 1.0M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.45 | 98.15 |
| EPS | 0.09 | ★ 0.77 |
| Revenue | ★ $588,907,000.00 | $29,868,000.00 |
| Revenue This Year | $4.16 | N/A |
| Revenue Next Year | $4.89 | $73.59 |
| P/E Ratio | $102.33 | ★ $21.10 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.21 | $6.24 |
| 52 Week High | $14.41 | $21.24 |
Technical Indicators
Market Signals| Indicator | EVCM | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 39.82 |
| Support Level | $8.55 | $16.50 |
| Resistance Level | $10.09 | $19.81 |
| Average True Range (ATR) | 0.44 | 0.81 |
| MACD | -0.00 | -0.38 |
| Stochastic Oscillator | 13.83 | 17.86 |
Price Performance
Historical ComparisonAbout EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.